
Please try another search
Breaking News
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SNY | NASDAQ | USD | Real-time | |
SANp | BATS Europe | EUR | Delayed | |
0O59 | London | EUR | Real-time | |
SNYN | Mexico | MXN | Delayed | |
SANF | Milan | EUR | Real-time | |
SASY | Frankfurt | EUR | Delayed | |
SASY | Xetra | EUR | Delayed | |
SASY | TradeGate | EUR | Delayed | |
SASY | Paris | EUR | Real-time |
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus US Government Calls For Additional Doses Of Pfizer/BioNTech COVID-19 Vaccine Pfizer Inc (NYSE:...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus US Government Calls For Additional Doses Of Pfizer/BioNTech COVID-19 Vaccine Pfizer Inc (NYSE: PFE)...
The FDA has placed Sanofi (EPA:SASY) SA's (NASDAQ: SNY) Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold. New enrollment in the U.S. is paused, and...
The FDA has placed Sanofi SA's (NASDAQ: SNY) Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold. New enrollment in the U.S. is paused, and...
(Reuters) – French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Europe Backs Novavax's COVID-19 Shot For Adolescents The European Union has recommended expanded...
Reuters Softbank’s Masayoshi Son Emphasizes Chances Of US Listing For Arm Softbank Group Corp (OTC: SFTBY) founder and CEO Masayoshi Son stressed the possibility of British-based chip designer...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Europe Backs Novavax's COVID-19 Shot For Adolescents The European Union has recommended expanded...
The companies reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron variant.
Sanofi and GlaxoSmithKline said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data to regulators. The recombinant...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review